Abstract
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is an indole-based secondary metabolite produced by numerous species of mushrooms. South American Aztec Indians referred to them as teonanacatl, meaning “god’s flesh,” and they were used in religious and healing rituals. Spanish missionaries in the 1500s attempted to destroy all records and evidence of the use of these mushrooms. Nevertheless, a 16th century Spanish Franciscan friar and historian mentioned teonanacatl in his extensive writings, intriguing 20th century ethnopharmacologists and leading to a decades-long search for the identity of teonanacatl. Their search ultimately led to a 1957 photo-essay in a popular magazine, describing for the Western world the use of these mushrooms. Specimens were ultimately obtained, and their active principle identified and chemically synthesized. In the past 10–15 years several FDA-approved clinical studies have indicated potential medical value for psilocybin-assisted psychotherapy in treating depression, anxiety, and certain addictions. At present, assuming that the early clinical studies can be validated by larger studies, psilocybin is poised to make a significant impact on treatments available to psychiatric medicine.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Nichols DE, Johnson MW, Nichols CD. Psychedelics as medicines: an emerging new paradigm. Clin Pharm Ther. 2017;101:209–19.
Wasson RG. Notes on the present status of ololiuhqui and the other hallucinogens of Mexico. Botanical Mus Leafl Harv Univ. 1963;20:161–93.
Corne SJ, Pickering RW. A possible correlation between drug-induced hallucinations in man and a behavioural response in mice. Psychopharmacologia. 1967;11:65–78.
Hofmann A, Heim R, Brack A, Kobel H. [Psilocybin, a psychotropic substance from the Mexican mushroom Psilicybe mexicana Heim]. Experientia. 1958;14:107–9.
Hofmann A, Frey A, Ott H, Petrzilka T, Troxler F. [Elucidation of the structure and the synthesis of psilocybin]. Experientia. 1958;14:397–9.
Psilocybin. In: O’Neil MJ, editor. The Merck Index—An encyclopedia of chemicals, drugs, and biologicals,. 13th ed. Whitehouse Station, NJ: Merck and Co., Inc.; 2001. p. 1419.
Baker RW, Chothia C, Pauling P, Weber HP. Molecular structure of LSD. Science. 1972;178:614–5.
Beug MW, Bigwood J. Psilocybin and psilocin levels in twenty species from seven genera of wild mushrooms in the Pacific Northwest, USA. J Ethnopharmacol. 1982;5:271–85.
Hofmann A. Teonanacatl and Ololuiqui and Ololuiqui, two ancient magic drugs of Mexico. Bull Narc. 1971;XXIII:3–14.
Horita A, Weber LJ. The enzymic dephosphorylation and oxidation of psilocybin and psilocin by mammalian tissue homogenates. Biochem Pharmacol. 1961;7:47–54.
Horita A. Some biochemical studies on psilocybin and psilocin. J Neuropsychiatry. 1963;4:270.
Hasler F, Bourquin D, Brenneisen R, Bar T, Vollenweider FX. Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv. 1997;72:175–84.
Nichols DE. Psychedelics. Pharm Rev.2016;68:264–355.
Nichols DE, Frescas S. Improvements to the synthesis of psilocybin and a facile method for preparing the O-acetyl prodrug of psilocin. Synthesis. 1999;6:935–8.
Shirota O, Hakamata W, Goda Y. Concise large-scale synthesis of psilocin and psilocybin, principal hallucinogenic constituents of “magic mushroom”. J Nat Prod. 2003;66:885–7.
Sherwood A, Meisenheimer P, Tarpley G, Kargbo R. An improved, practical, and scalable five-step synthesis of psilocybin. Synthesis. 2020;52:688–94.
Kargbo R, Sherwood A, Kaylo K, Meisenheimer P, O’Hern K, Patterson T, et al. The First Direct Phosphorylation of Psilocin to Psilocybin under cGMP Conditions. International Society for Research on Psychedelics. New Orleans 2019.
Agurell S, Nilsson JL. A biosynthetic sequence from tryptophan to psilocybin. Tetrahedron Lett. 1968;9:1063–4.
Agurell S, Nilsson JL. Biosynthesis of psilocybin. II. Incorporation of labelled tryptamine derivatives. Acta Chem Scand. 1968;22:1210–8.
Fricke J, Blei F, Hoffmeister D. Enzymatic synthesis of psilocybin. Angew Chem Int Ed Engl. 2017;56:12352–5.
Adams AA, Kaplan NA, Wei Z, Brinton JD, Monnier CS, Enacopol AL, et al. In vivo production of psilocybin in E. coli. Metab Eng. 2019;56:111–9.
Fricke J, Kargbo R, Regestein L, Lenz C, Peschel G, Rosenbaum M, et al. Scalable hybrid synthetic/biocatalytic route to psilocybin. Chemistry. 2020. https://doi.org/10.1002/chem.202000134.
Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67:1735–40.
Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacol. 2006;187:268–83.
Maclean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011;25:1453–61.
Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68:71–8.
Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28:983–92.
Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29:289–99.
Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30:1181–97.
Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30:1165–80.
Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology. 1997;16:357–72.
Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, et al. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology. 1999;20:565–81.
Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci USA. 2012;109:2138–43.
Lewis CR, Preller KH, Kraehenmann R, Michels L, Staempfli P, Vollenweider FX. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. Neuroimage. 2017;159:70–8.
Muthukumaraswamy SD, Carhart-Harris RL, Moran RJ, Brookes MJ, Williams TM, Errtizoe D, et al. Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci. 2013;33:15171–83.
Beique JC, Imad M, Mladenovic L, Gingrich JA, Andrade R. Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci USA. 2007;104:9870–5.
Martin DA, Nichols CD. Psychedelics recruit multiple cellular types and produce complex transcriptional responses within the brain. EBioMedicine. 2016;11:262–77.
Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T, et al. Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Br J Psychiatry. 2012;200:238–44.
Petri G, Expert P, Turkheimer F, Carhart-Harris R, Nutt D, Hellyer PJ, et al. Homological scaffolds of brain functional networks. J R Soc Interface. 2014;11:20140873.
Barrett FS, Doss MK, Sepeda ND, Pekar JJ, Griffiths RR. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep. 2020;10:2214.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author declares that he has no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Nichols, D.E. Psilocybin: from ancient magic to modern medicine. J Antibiot 73, 679–686 (2020). https://doi.org/10.1038/s41429-020-0311-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41429-020-0311-8
This article is cited by
-
Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study
Nature Medicine (2023)
-
Psilocybin in Palliative Care: An Update
Current Geriatrics Reports (2023)
-
Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy
Molecular Biotechnology (2023)
-
Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality
Scientific Reports (2022)
-
Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review
Psychopharmacology (2022)